The key answer to your key question regarding "how thorough and truly diligent have the Board and Wotton been in meeting their fiduciary responsibilities in getting the best value for shareholders when selling Ocata?"
Not very, IMO.
A fairly major piece of research Dr Lanza had released yesterday and no PR. Lanza had to release it himself on Twitter. Sad, really. I know they have 3 days to release it according to the SEC guidelines, but it's GOOD NEWS. Why bury good news close to the holiday except for malicious intent? They've never wanted to create value, IMO. At least not since the JV talks evolved into a buyout.
During PW's time, I can recall several times we all scratched our heads at some of his actions. For example, announcing more dilution right into the rally of uplisting. They already knew Astellas wanted to buy at that point, but we didn't.
I have no doubt that these trials have been purposefully held up. We were told on the conference call, hours before the buyout was made public, that 5 new trial sites would be up and running by the end of November. Where are they? "The bar was set too high" to find subjects to include in the trials design, but we will still see no delay in preliminary result readout early 2016? How does that happen? Blowing smoke up our arse, that's how. I have no question of that in my mind. Fiduciary duties weren't upheld for quite some time, IMO.
Can you, or anyone, say for sure where Ocata could be in relation to marketing a product IF the CEO was concentrated on injecting patients and creating value, instead of selling the company? I don't want to hear ppl say they were cash poor, etc...They had enough money to fund through the preliminary results, just voluntarily chose not to advance. Selling this company has been PW's one and only objective, IMO.
I just hope everyone gets what's coming to them.
News 
Market Data 
Discover 
